ClinicalTrials.gg
CompletedNCT02733042FUSION NHL 001Updated Nov 18, 2023Results posted

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

A Phase 1/2 interventional study of Durvalumab and Lenalidomide in Lymphoma and Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Celgene. Completed at 66 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 42 studies in Lymphoma by Bristol-Myers Squibb — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Bristol-Myers Squibb.

Enrollment
12th of 39
106 · median 74
Started
2016
with 2 others
Phase 1/2
6 of 42
1 open now
Registered
23rd of 42
by date

Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2016, is one of 6 in phase 1/2, and was the 23rd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 42 studies in Lymphoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Lymphoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab at the RP2D in adults with lymphoma or chronic lymphocytic leukemia (CLL).

Read the detailed description

The study was to consist of 3 parts: dose-finding, dose-confirmation, and dose-expansion. In this study, 4 treatment arms were to be investigated:

  • Arm A: durvalumab and lenalidomide ± rituximab
  • Arm B: durvalumab and ibrutinib
  • Arm C: durvalumab and rituximab ± bendamustine
  • Arm D: durvalumab (monotherapy)

The study was to start with 3 dose-finding cohorts (Arms A, B, and C) and 1 dose-confirmation cohort (Arm D) in parallel. All treatment arms were to be open for enrollment at study start except in the US, where Arm D was to enroll depending on the availability of treatment slots and following the completion of assessment of responses from the combination therapy arms. For Arms A and C, prior to enrolling participants to receive all 3 drugs, the doublet combinations were to be evaluated. Once the doublet combinations were deemed tolerable, the eventual triplet combinations were to be tested.

On 05 September 2017, the US FDA issued a Partial Clinical Hold on the study Arm A. Following this Partial Clinical Hold no more participants were enrolled into study Arm A. Participants already enrolled and treated in Arm A who were receiving clinical benefit, based on the discretion of the investigator, could continue study treatment after being reconsented. Arm B and C completed dose confirmation. The dose expansion part of the study was not opened.

03

Conditions studied

  • Lymphoma
  • Leukemia, Lymphocytic, Chronic, B-Cell

Keywords

  • Lymphoma
  • Chronic Lymphocytic Leukemia
  • Durvalumab
  • Anti-PD-L1 Antibody
  • MEDI4736
  • Immune Checkpoint
  • Lymphatic Disease
  • B-Cell Malignancies
  • Abscopal Effect
  • Lenalidomide
  • Bendamustine
  • Rituximab
  • Ibrutinib
  • Lymphoma, B-Cell
  • Lymphoma, Non Hodgkin,
  • Hodgkin Disease
  • Leukemia, Lymphocytic, Chronic, B-Cell,
  • Lymphoma, Follicular
  • Lymphoma, Diffuse Large B-Cell
  • Lymphoma, Mantle Cell
  • Lymphoma, Small Lymphocytic
  • Immune System Diseases
  • Immunoproliferative Disorders
  • Lymphoproliferative Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject who has confirmed and documented B-cell lymphoma (eg, follicular, diffuse large B-cell, mantle cell, small lymphocytic, or Hodgkin lymphoma) and chronic lymphocytic leukemia.
  2. Subject who has high-risk chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  3. Subject who was previously treated with at least one prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy.
  4. Subject who has the performance status of 0, 1, or 2.
  5. Subject who is willing and able to undergo .
  6. Subject who has documented active disease requiring therapeutic intervention.
  7. Subject with lymphoma who has (≥ 2.0 cm in its longest dimension by computed tomography) or chronic lymphocytic leukemia in need of treatment.
  8. Subject who fulfills the laboratory requirements as per protocol

Exclusion criteria

Exclusion Criteria

  1. Subject who has central nervous system (CNS) or meningeal involvement by lymphoma.
  2. Subject who has any histopathologic finding consistent with myelodysplastic syndrome on bone marrow studies.
  3. Subject who received any prior monoclonal antibodies against programmed cell death-1 () or programmed cell death ligand-1 (PD-L1) and/or any prior:

    1. Arm A only: drugs with immunomodulatory and other properties (eg, lenalidomide, thalidomide);
    2. Arm B only: ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitor;
    3. Arms C only: bendamustine
  4. Subject who has active auto-immune disease.
  5. Subject who has history of organ transplant or hematopoietic stem cell transplantation.
  6. Subject who is seropositive for or active viral infection with virus (HBV) (hepatitis B surface antigen [HBsAg] positive and/or detectable viral DNA)
  7. Subject who has known seropositivity for or active infection for (HIV) or virus (HCV).
  8. Subject who has history of primary immunodeficiency or tuberculosis.
  9. Subject who other invasive within 2 years (5 years for Arm A) except for noninvasive malignancies such as cervical carcinoma in situ, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast, or incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, ] clinical staging system) that has/have been surgically cured.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Arm A: Durvalumab + Lenalidomide ± Rituximab

    Participants assigned to Arm A will receive: * Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and * Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of: * Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or * All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL * Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5. All treatment cycles were 28 days.

    Drug: Durvalumab · Drug: Lenalidomide · Drug: Rituximab

  • Experimental
    Arm B: Durvalumab + Ibrutinib

    Participants assigned to Arm B will receive: * Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13 * Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason. All treatment cycles were 28 days.

    Drug: Durvalumab · Drug: Ibrutinib

  • Experimental
    Arm C: Durvalumab + Rituximab ± Bendamustine

    Participants assigned to Arm C will receive: * Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13 * Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose) * Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6. All treatment cycles were 28 days.

    Drug: Durvalumab · Drug: Rituximab · Drug: Bendamustine

  • Experimental
    Arm D: Durvalumab Monotherapy

    Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.

    Drug: Durvalumab

Interventions

  • Administered as an IV infusion (250 mL) over approximately 1 hour in duration

    Also known as: MEDI4736, IMFINZI®

  • Administered orally

    Also known as: Revlimid®

  • Administered by intravenous infusion

    Also known as: Rituxan®, MabThera®

  • Administered orally

    Also known as: Imbruvica®

  • Administered as a 30-minute intravenous infusion

    Also known as: Treanda®, Bendeka®, Levact®

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    Dose limiting toxicities were evaluated during the DLT evaluation period for participants in the dose finding cohorts. The severity grading was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT is defined as below: Hematologic DLT • Grade 4 neutropenia observed for greater than 5 days duration • Grade 3 neutropenia associated with fever (≥ 38.5 °C) of any duration • Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or any requirement for platelets transfusion • Grade 4 anemia, unexplained by underlying disease • Any other grade 4 hematologic toxicity that does not resolve to participant's pretreatment baseline level within 72 hours. Non-Hematologic DLT • Any non-hematological toxicity ≥ Grade 3 except for alopecia and nausea controlled by medical management • Any treatment interruption greater than 2 weeks due to adverse event.

    Time frame: Cycle 1 (28 days)

  2. Number of Participants With Treatment-emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) occurring or worsening on or after the first dose of any study treatment (durvalumab, lenalidomide, ibrutinib, bendamustine or rituximab) and within 90 days after last dose of durvalumab or 28 days after the last dose of other study drugs, whichever was later, as well as those serious adverse events made known to the investigator at any time thereafter that were suspected of being related to study treatment. The intensity of AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death (Grade 5).

    Time frame: From first dose of any study drug to 90 days after last dose of durvalumab or 28 days after last dose of other study drugs, up to the data cut-off date of 6 March 2019. Maximum time on treatment was 55.4 weeks for DUR and 130 weeks for other study drugs.

Secondary outcomes

  1. Overall Response Rate (ORR) During Durvalumab Treatment

    For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percent of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).

    Time frame: Up to 13 cycles (12 months)

  2. Overall Response Rate During the Entire Study

    For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification) (Cheson, 2014). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percentage of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).

    Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.

  3. Time to First Response

    Time to response was calculated as the time from first dose of study drug to the first response date (CR or PR for lymphoma participants and CR, CRi, nPR, PR, or PRL for CLL participants).

    Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.

  4. Kaplan-Meier Estimate of Duration of Response

    Duration of response is defined for responders only as the time from the first documented response (CR or PR for lymphoma participants or CR, CRi, nPR, PR, or PRL for CLL participants) to disease progression or death (from any cause). For participants with response but no progression, or death, duration of response was censored at the last date that the participant was known to be progression-free.

    Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.

  5. Kaplan-Meier Estimate of Progression-free Survival (PFS)

    Progression-free survival was calculated as the time from first dose of study drug to the first documented progression or death (from any cause) during the entire efficacy evaluation period. For participants with no progression or death, PFS was censored at the last assessment date the participant was known to be progression-free.

    Time frame: From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.

  6. Maximum Observed Plasma Concentration (Cmax) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  7. Time to Maximum Plasma Concentration (Tmax) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  8. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  9. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  10. Terminal Elimination Phase Half-Life (t½) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  11. Clearance (CL) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  12. Volume of Distribution (Vz) of Durvalumab

    Time frame: Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.

  13. Maximum Observed Plasma Concentration (Cmax) of Lenalidomide

    Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.

  14. Time to Maximum Observed Plasma Concentration (Tmax) of Lenalidomide

    Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.

  15. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide

    Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose

  16. Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

    Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.

  17. Time to Maximum Observed Plasma Concentration (Tmax) of Ibrutinib

    Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.

  18. Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib

    Time frame: Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose

  19. Change From Baseline in Soluble Programmed Cell Death Ligand-1 (sPD-L1) Concentration

    Change from baseline in sPD-L1 could not be calculated as all post-baseline samples were below the lower limit of quantification (\<15.60 pg/mL).

    Time frame: Baseline (Cycle 1 Day 1 predose) and Day 1 of Cycles 2 to 13

07

Results

Posted Mar 18, 2020
Limitations and caveats
The study was placed on full clinical hold by the United States (US) Food and Drug Administration (FDA) on 05 Sep 2017. As the result, the study was closed for further enrollment, and all participants were discontinued from all study treatments (durvalumab, lenalidomide and dexamethasone). All participants were followed for second primary malignancies (SPMs) for 5 years after the last participant has been enrolled as per protocol.

Participant flow

Participant flow — Overall Study
MilestonePart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Started338343145101010105510255
Participants who entered follow-up period after completing/discontinuing study treatment3363220444599415032
Completed0110100106441100001
Not completed32733313546694510254
Withdrew: Adverse event1011000000220200010
Withdrew: Progressive disease2131230332228147234
Withdrew: Withdrawal by subject0121100011021100000
Withdrew: Other reasons0010000001100001010
Withdrew: Death0000001010100012000

Outcome measures

PrimaryPart 1: Number of Participants With Dose Limiting Toxicities (DLTs)

Dose limiting toxicities were evaluated during the DLT evaluation period for participants in the dose finding cohorts. The severity grading was determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03. A DLT is defined as below: Hematologic DLT • Grade 4 neutropenia observed for greater than 5 days duration • Grade 3 neutropenia associated with fever (≥ 38.5 °C) of any duration • Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding, or any requirement for platelets transfusion • Grade 4 anemia, unexplained by underlying disease • Any other grade 4 hematologic toxicity that does not resolve to participant's pretreatment baseline level within 72 hours. Non-Hematologic DLT • Any non-hematological toxicity ≥ Grade 3 except for alopecia and nausea controlled by medical management • Any treatment interruption greater than 2 weeks due to adverse event.

Time frame:
Cycle 1 (28 days)
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)031000—01
Statistical analysis
  • Part 1, Arm B: DUR 1500 mg + IBR 420 mg vs Part 1, Arm B: DUR 1500 mg + IBR 560 mg ·
  • Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² vs Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m² vs Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m² vs Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m² ·
PrimaryNumber of Participants With Treatment-emergent Adverse Events

Treatment-emergent adverse events (TEAEs) are defined as adverse events (AEs) occurring or worsening on or after the first dose of any study treatment (durvalumab, lenalidomide, ibrutinib, bendamustine or rituximab) and within 90 days after last dose of durvalumab or 28 days after the last dose of other study drugs, whichever was later, as well as those serious adverse events made known to the investigator at any time thereafter that were suspected of being related to study treatment. The intensity of AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. For all other AEs not described in the CTCAE criteria, the intensity was assessed by the investigator as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death (Grade 5).

Time frame:
From first dose of any study drug to 90 days after last dose of durvalumab or 28 days after last dose of other study drugs, up to the data cut-off date of 6 March 2019. Maximum time on treatment was 55.4 weeks for DUR and 130 weeks for other study drugs.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Any TEAE3383431451010109559255
TEAE Related to Any Study Drug338343045109109543032
CTCAE Grade 3-4 TEAE13723213481069547143
CTCAE Grade 3-4 TEAE Related to Any Study Drug1371120227657332011
CTCAE Grade 5 TEAE0000000000100114000
CTCAE Grade 5 TEAE Related to Any Study Drug0000000000100000000
Serious TEAE1242221136755247032
Serious TEAE Related to Any Study Drug1231010012333131000
TEAE Leading to Discontinuation of Any Study Drug1031000000221210010
TEAE Leading to Dose Modifications of Study Drug1333431448974320033
SecondaryOverall Response Rate (ORR) During Durvalumab Treatment

For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percent of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).

Time frame:
Up to 13 cycles (12 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) During Durvalumab Treatment
percentage of participantsPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Overall Response Rate (ORR) During Durvalumab Treatment33.3 (0.8 to 90.6)66.7 (9.4 to 99.2)80.0 (28.4 to 99.5)66.7 (9.4 to 99.2)75.0 (19.4 to 99.4)33.3 (0.8 to 90.6)—50.0 (6.8 to 93.2)0 (NA to NA)88.9 (51.8 to 99.7)60.0 (26.2 to 87.8)88.9 (51.8 to 99.7)30.0 (6.7 to 65.2)50.0 (6.8 to 93.2)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)20.0 (0.5 to 71.6)
SecondaryOverall Response Rate During the Entire Study

For lymphoma participants, response evaluation was based on International Working Group (IWG) response criteria for malignant lymphoma (the Lugano Classification) (Cheson, 2014). Overall response rate is defined as the percent of participants with best response of complete response (CR) or partial response (PR). For chronic lymphocytic leukemia participants, response evaluation was based on International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for diagnosis and treatment of CLL. The ORR is defined as the percentage of participants with best response of CR, complete response with incomplete marrow recovery (CRi), nodular partial response (nPR), PR, or partial response with lymphocytosis (PRL).

Time frame:
From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Reported as:
Number · percentage of participants
Overall Response Rate During the Entire Study
percentage of participantsPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Overall Response Rate During the Entire Study66.7 (9.4 to 99.2)66.7 (9.4 to 99.2)80.0 (28.4 to 99.5)66.7 (9.4 to 99.2)75.0 (19.4 to 99.4)33.3 (0.8 to 90.6)—50.0 (6.8 to 93.2)0 (NA to NA)100.0 (66.4 to 100.0)70.0 (34.8 to 93.3)88.9 (51.8 to 99.7)30.0 (6.7 to 65.2)50.0 (6.8 to 93.2)0 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)20.0 (0.5 to 71.6)
SecondaryTime to First Response

Time to response was calculated as the time from first dose of study drug to the first response date (CR or PR for lymphoma participants and CR, CRi, nPR, PR, or PRL for CLL participants).

Time frame:
From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Reported as:
Median · weeks
Time to First Response
weeksPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Time to First Response70.85 (12.1 to 129.6)12.60 (12.1 to 13.1)18.20 (11.3 to 36.1)11.85 (11.4 to 12.3)13.40 (12.4 to 52.9)13.00 (13.0 to 13.0)—13.10 (12.1 to 14.1)—12.10 (10.9 to 72.9)12.10 (6.6 to 26.4)12.35 (10.3 to 15.3)12.00 (8.7 to 12.1)12.10 (12.1 to 12.1)————13.10 (13.1 to 13.1)
SecondaryKaplan-Meier Estimate of Duration of Response

Duration of response is defined for responders only as the time from the first documented response (CR or PR for lymphoma participants or CR, CRi, nPR, PR, or PRL for CLL participants) to disease progression or death (from any cause). For participants with response but no progression, or death, duration of response was censored at the last date that the participant was known to be progression-free.

Time frame:
From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Reported as:
Median · weeks
Kaplan-Meier Estimate of Duration of Response
weeksPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Kaplan-Meier Estimate of Duration of Response10.14 (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)29.29 (NA to NA)—NA (NA to NA)—NA (NA to NA)NA (NA to NA)NA (NA to NA)24.14 (9.14 to 26.14)NA (NA to NA)————11.14 (NA to NA)
SecondaryKaplan-Meier Estimate of Progression-free Survival (PFS)

Progression-free survival was calculated as the time from first dose of study drug to the first documented progression or death (from any cause) during the entire efficacy evaluation period. For participants with no progression or death, PFS was censored at the last assessment date the participant was known to be progression-free.

Time frame:
From first dose of any study drug to the end of follow-up, up to the data cutoff date of March 6, 2019; median (minimum, maximum) time on study was 16.7 (0.9, 32.9) months.
Reported as:
Median · months
Kaplan-Meier Estimate of Progression-free Survival (PFS)
monthsPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Kaplan-Meier Estimate of Progression-free Survival (PFS)8.41 (5.09 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)28.71 (4.50 to NA)9.69 (1.64 to 12.68)1.25 (NA to NA)3.82 (1.25 to NA)2.48 (0.49 to 5.91)NA (NA to NA)NA (NA to NA)14.65 (5.75 to 14.65)2.06 (0.76 to 8.28)NA (NA to NA)1.68 (0.69 to 4.63)1.17 (0.26 to 3.19)2.76 (2.50 to 3.02)2.33 (0.79 to 10.02)2.66 (2.56 to 5.98)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Geometric mean · μg/L
Maximum Observed Plasma Concentration (Cmax) of Durvalumab
μg/LArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Maximum Observed Plasma Concentration (Cmax) of Durvalumab420264.066 ± 22.7361906.229 ± 30.1331572.478 ± 33.4392663.668 ± 41.1
SecondaryTime to Maximum Plasma Concentration (Tmax) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Median · days
Time to Maximum Plasma Concentration (Tmax) of Durvalumab
daysArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Time to Maximum Plasma Concentration (Tmax) of Durvalumab0.0510 (0.042 to 1.035)0.0479 (0.041 to 1.061)0.0510 (0.042 to 6.788)0.0420 (0.038 to 1.986)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Geometric mean · days*μg/L
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab
days*μg/LArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Durvalumab3120149.759 ± 29.53225869.344 ± 31.92670168.397 ± 46.73053060.746 ± 37.8
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Geometric mean · days*μg/L
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab
days*μg/LArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) of Durvalumab4867431.378 ± 23.35818262.846 ± 42.14762968.345 ± 71.05593532.553 ± 53.0
SecondaryTerminal Elimination Phase Half-Life (t½) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Geometric least squares mean · days
Terminal Elimination Phase Half-Life (t½) of Durvalumab
daysArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Terminal Elimination Phase Half-Life (t½) of Durvalumab11.596 ± 46.617.344 ± 47.316.327 ± 57.415.399 ± 53.5
SecondaryClearance (CL) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Geometric least squares mean · L/day
Clearance (CL) of Durvalumab
L/dayArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Clearance (CL) of Durvalumab0.3082 ± 23.30.2578 ± 42.10.3149 ± 71.00.2682 ± 53.0
SecondaryVolume of Distribution (Vz) of Durvalumab
Time frame:
Cycle 1, Day 1 (pre-dose and at end of infusion), and 4, 24, 48, 168 (Day 8), 336 (Day 15), and 508 (Day 22) hours after the end of infusion.
Reported as:
Geometric least squares mean · liters
Volume of Distribution (Vz) of Durvalumab
litersArm A: Durvalumab + Lenalidomide ± RituximabArm B: Durvalumab + IbrutinibArm C: Durvalumab + Bendamustine ± RituximabArm D: Durvalumab Monotherapy
Volume of Distribution (Vz) of Durvalumab5.155 ± 41.96.451 ± 38.37.418 ± 33.75.957 ± 33.0
SecondaryMaximum Observed Plasma Concentration (Cmax) of Lenalidomide
Time frame:
Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Reported as:
Geometric least squares mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Lenalidomide
ng/mLArm A: Lenalidomide 10 mgArm A: Lenalidomide 20 mg
Cycle 1 Day 1141.881 ± 22.0309.917 ± 6.9
Cycle 1 Day 15107.635 ± 40.9174.090
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Lenalidomide
Time frame:
Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Lenalidomide
hoursArm A: Lenalidomide 10 mgArm A: Lenalidomide 20 mg
Cycle 1 Day 11.9500 (1.000 to 3.917)1.1667 (1.000 to 1.433)
Cycle 1 Day 153.0333 (1.233 to 4.000)1.000 (1.000 to 1.000)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide
Time frame:
Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose
Reported as:
Geometric least squares mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide
h*ng/mLArm A: Lenalidomide 10 mgArm A: Lenalidomide 20 mg
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Lenalidomide789.297 ± 84.3805.299 ± 56.0
SecondaryMaximum Observed Plasma Concentration (Cmax) of Ibrutinib
Time frame:
Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Reported as:
Geometric least squares mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Ibrutinib
ng/mLArm B: Ibrutinib 420 mgArm B: Ibrutinib 560 mg
Cycle 1 Day 1129.704 ± 98.067.728 ± 197.9
Cycle 1 Day 1586.840 ± 136.972.436 ± 166.3
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
Time frame:
Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose, and Cycle 1 Day 15 at pre-dose, 1, 2, and 4 hours post-dose.
Reported as:
Median · hours
Time to Maximum Observed Plasma Concentration (Tmax) of Ibrutinib
hoursArm B: Ibrutinib 420 mgArm B: Ibrutinib 560 mg
Cycle 1 Day 12.000 (0.000 to 4.367)1.9333 (0.933 to 3.917)
Cycle 1 Day 151.8833 (1.000 to 4.000)2.000 (1.000 to 4.083)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib
Time frame:
Cycle 1 Day 1 at predose and 1, 2, 4, and 24 hours post-dose
Reported as:
Geometric least squares mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib
h*ng/mLArm B: Ibrutinib 420 mgArm B: Ibrutinib 560 mg
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUClast) of Ibrutinib586.396 ± 117.2436.855 ± 246.5
SecondaryChange From Baseline in Soluble Programmed Cell Death Ligand-1 (sPD-L1) Concentration

Change from baseline in sPD-L1 could not be calculated as all post-baseline samples were below the lower limit of quantification (\<15.60 pg/mL).

Time frame:
Baseline (Cycle 1 Day 1 predose) and Day 1 of Cycles 2 to 13

No measurements were reported for this outcome.

Post-hocNumber of Participants With Treatment-emergent Adverse Events (TEAEs) - Extended Collection

TEAEs defined as AEs occurring or worsening on or after first dose of any study treatment (durvalumab, lenalidomide, ibrutinib, bendamustine or rituximab) and within 90 days after last dose of durvalumab or 28 days after the last dose of other study drugs, whichever was later, as well as those serious adverse events made known to the investigator at any time thereafter that were suspected of being related to study treatment. Intensity of AEs graded according to the NCI CTCAE V. 4.03. For all other AEs not described in the CTCAE criteria, the intensity was assessed by investigator as mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death (Grade 5). This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date (assessments made until August 21, 2022).

Time frame:
From first dose of any study drug to 90 days after last dose of durvalumab or 28 days after last dose of other study drugs, up to the study completion date of August 21, 2022 (up to approximately 75 months).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) - Extended Collection
ParticipantsPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
Any TEAE3383431451010109559255
TEAE Related to Any Study Drug338343045109109543032
CTCAE Grade 3-4 TEAE13724213491069547143
CTCAE Grade 3-4 TEAE Related to Any Study Drug1371120228657332011
CTCAE Grade 5 TEAE0000000000100114000
CTCAE Grade 5 TEAE Related to Any Study Drug0000000000100000000
Serious TEAE1242321136755247032
Serious TEAE Related to Any Study Drug1231010013333131000
TEAE Leading to Discontinuation of Any Study Drug1031000000221210010
TEAE Leading to Dose Modifications of Study Drug1353431449974320033

Adverse events

Collected over All-cause mortality was assessed from the participants first dose to their study completion (up to approximately 75 months). SAEs and Other AEs were assessed from first dose to 90 days from the last dose of durvalumab or 28 days from the last dose of any other study treatment [ie, lenalidomide, ibrutinib, rituximab, bendamustine, or involved field radiation (IFRT) therapy], whichever occurs later (up to approximately 75 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1, Arm A: DUR 1500 mg + LEN 20 mg1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Part 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²2/8 (25%)4/8 (50%)8/8 (100%)
Part 1, Arm B: DUR 1500 mg + IBR 420 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Part 1, Arm B: DUR 1500 mg + IBR 560 mg3/4 (75%)3/4 (75%)4/4 (100%)
Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m²2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²1/1 (100%)1/1 (100%)1/1 (100%)
Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²3/4 (75%)1/4 (25%)4/4 (100%)
Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²4/5 (80%)3/5 (60%)5/5 (100%)
Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mg1/10 (10%)6/10 (60%)10/10 (100%)
Part 2, Arm B MCL: DUR 1500 mg + IBR 560 mg2/10 (20%)7/10 (70%)10/10 (100%)
Part 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²0/10 (0%)5/10 (50%)10/10 (100%)
Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²9/10 (90%)5/10 (50%)9/10 (90%)
Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²2/5 (40%)2/5 (40%)5/5 (100%)
Part 2, Arm D FL: DUR 1500 mg4/5 (80%)4/5 (80%)5/5 (100%)
Part 2, Arm D DLBCL: DUR 1500 mg9/10 (90%)8/10 (80%)10/10 (100%)
Part 2, Arm D CLL/SLL: DUR 1500 mg0/2 (0%)0/2 (0%)2/2 (100%)
Part 2, Arm D MCL: DUR 1500 mg4/5 (80%)4/5 (80%)5/5 (100%)
Part 2, Arm D HL: DUR 1500 mg4/5 (80%)2/5 (40%)5/5 (100%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
SepsisInfections and infestations0/31/31/80/30/40/31/10/40/50/100/100/100/101/51/50/100/20/51/5
Acute kidney injuryRenal and urinary disorders0/31/30/80/31/40/31/10/40/51/100/100/100/100/50/50/100/20/50/5
General physical health deteriorationGeneral disorders0/30/30/80/30/40/30/10/41/50/100/100/100/100/50/52/100/22/51/5
PyrexiaGeneral disorders0/31/31/80/30/41/30/10/40/50/101/100/101/100/51/50/100/20/52/5
Febrile neutropeniaBlood and lymphatic system disorders1/30/31/80/30/40/30/10/40/51/100/101/100/100/50/50/100/20/50/5
NeutropeniaBlood and lymphatic system disorders0/31/30/80/30/40/30/10/40/50/100/100/100/100/50/50/100/20/50/5
ThrombocytopeniaBlood and lymphatic system disorders0/31/30/80/30/40/30/10/41/50/100/100/100/100/50/50/100/20/50/5
DiarrhoeaGastrointestinal disorders0/30/30/80/30/41/30/10/40/50/100/100/100/100/50/50/100/21/50/5
Rectal haemorrhageGastrointestinal disorders0/30/30/80/30/41/30/10/40/50/100/100/100/100/50/50/100/20/50/5
Generalised oedemaGeneral disorders0/30/30/80/30/41/30/10/40/50/100/100/100/100/51/50/100/20/50/5
Most frequent other events
Showing 10 of 372
Most frequent other events
EventPart 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mg
AnaemiaBlood and lymphatic system disorders2/30/33/80/32/40/30/11/43/50/103/101/105/101/51/52/102/21/52/5
NeutropeniaBlood and lymphatic system disorders1/31/34/81/31/41/30/12/41/54/103/106/103/101/50/53/102/23/51/5
ThrombocytopeniaBlood and lymphatic system disorders0/31/32/80/32/40/30/11/42/53/103/102/106/101/51/54/102/23/51/5
ConstipationGastrointestinal disorders3/31/34/80/33/41/30/11/40/51/102/103/101/101/52/50/100/20/50/5
DiarrhoeaGastrointestinal disorders1/31/32/83/32/41/30/11/41/55/105/102/101/101/51/50/100/22/53/5
AstheniaGeneral disorders1/30/30/81/31/41/30/10/40/50/102/101/103/100/51/52/102/23/52/5
Skin infectionInfections and infestations0/30/30/80/30/40/31/10/40/50/100/101/100/101/50/50/100/20/50/5
MyalgiaMusculoskeletal and connective tissue disorders2/33/30/80/31/40/30/10/40/52/100/100/100/100/50/50/100/20/50/5
Upper gastrointestinal haemorrhageGastrointestinal disorders0/30/30/80/30/40/31/10/40/50/100/100/100/100/50/50/100/20/50/5
PyrexiaGeneral disorders1/31/32/80/31/41/30/11/43/53/102/103/104/101/52/56/101/24/52/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
Median71.0 (50 to 78)66.0 (52 to 75)77.0 (53 to 80)58.0 (54 to 74)68.0 (57 to 81)79.0 (76 to 80)70.0 (70 to 70)68.0 (52 to 78)38.0 (21 to 77)68.0 (55 to 73)73.5 (54 to 84)64.5 (45 to 75)60.0 (46 to 71)68.0 (53 to 79)52.0 (39 to 71)61.5 (22 to 76)62.0 (55 to 69)77.0 (69 to 80)51.0 (34 to 65)67.0 (21 to 84)
Age, Customized
Age, Customized(Participants)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
< 65 Years112210013425723510444
≥ 65 Years226133132685332515162
Sex: Female, Male
Sex: Female, Male(Participants)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
Female102022013313422412235
Male236321132797633613371
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
Hispanic or Latino00001000000001000002
Not Hispanic or Latino227231133576832925576
Unknown or Not Reported111102012534213100028
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
White223240104564442924563
Asian003000031011300001013
Black or African American00000000000100000001
American Indian or Alaska Native00000000000000000000
Native Hawaiian or Other Pacific Islander00000000000000000000
Other00100000000010000002
Not Collected or Reported111103010534213100027
Histology
Histology(Participants)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
Follicular lymphoma1311010100010005000023
Diffuse large B-cell lymphoma20400213500010001000037
Marginal zone lymphoma00203000000000000005
Transformed follicular lymphoma00100000000000000001
Mantle cell lymphoma0001100000100000005017
CLL / SLL0001000001000050020018
Hodgkin lymphoma00000000000000000055
Eastern Cooperative Oncology Group ECOG) Performance Status
Eastern Cooperative Oncology Group ECOG) Performance Status(Participants)Part 1, Arm A: DUR 1500 mg + LEN 20 mgPart 1, Arm A: DUR 1500 mg + LEN 20 mg + RIT 375 mg/m²Part 1, Arm A: DUR 1500 mg + LEN 10 mg + RIT 375 mg/m²Part 1, Arm B: DUR 1500 mg + IBR 420 mgPart 1, Arm B: DUR 1500 mg + IBR 560 mgPart 1, Arm C: DUR 1500 mg + RIT 375 mg/m²Part 1, Arm C: DUR 1500 mg + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 1, Arm C: DUR 1500 mg + RIT 375 mg/m² + BEN 90 mg/m²Part 2, Arm B CLL/SLL: DUR 1500 mg + IBR 420 mgPart 2, Arm B MCL: DUR 1500 mg + IBR 560 mgPart 2, Arm C FL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2 Arm C DLBCL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm C CLL/SLL: DUR 1500 mg + RIT 375 mg/m² + BEN 70 mg/m²Part 2, Arm D FL: DUR 1500 mgPart 2, Arm D DLBCL: DUR 1500 mgPart 2, Arm D CLL/SLL: DUR 1500 mgPart 2, Arm D MCL: DUR 1500 mgPart 2, Arm D HL: DUR 1500 mgTotal
0 - Fully Active022011032866702314553
1 - Restricted but ambulatory314332002233142411039
2 - Ambulatory but unable to work002000111011211200013
3 - Limited self-care00000000000000010001
08

Study locations

66 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Pinnacle Oncology Hematology
    Scottsdale, Arizona 85258, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • Shands Cancer Center University of Florida
    Gainesville, Florida 32610, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Local Institution - 005
    Rochester, New York 14642, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • University of Oklahoma Peggy and Charles Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Jefferson Medical Oncology Associates
    Philadelphia, Pennsylvania 19107, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Centre Hospitalier Universitaire d'Avicennes
    Bobigny Cedex, 93009, France
  • Hopital Henri Mondor
    Creteil, 94010, France
  • Centre Hospitalier
    Dijon Cedex, 21079, France
  • Institut Paoli Calmettes
    Marseille Cedex 9, 13273, France
  • CHU Montpellier
    Montpellier Cedex 5, 34295, France
  • Local Institution - 102
    Montpellier Cedex 5, 34295, France
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44093, France
  • Local Institution - 105
    Nantes, 44093, France
  • Hopital Haut Leveque
    Pessac Cedex, 33604, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Benite CEDEX, 69495, France
  • Local Institution - 103
    Pierre-Benite CEDEX, 69495, France
  • CHRU Rennes
    Rennes, 35033, France
  • Centre Henri Becquerel
    Rouen Cedex, 76038, France
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • UKG Universitatsklinikum Gottingen
    Göttingen, 37099, Germany
  • Universitatsklinikum des Saarlandes
    Homburg-Saar, 66421, Germany
  • Universitatsklinik Koln
    Köln, 50924, Germany
  • Medizinische Klinik III Klinikum der Universität München-Großhadern
    München, 81377, Germany
  • University of Bologna
    Bologna, 40138, Italy
  • Local Institution - 306
    Brescia, 25123, Italy
  • Spedali Civili Di Brescia
    Brescia, 25123, Italy
  • IEO- Istituto Europeo di Oncologia
    Milano, 20144, Italy
  • A.O. Ospedale Ca Granda - Niguarda
    Milano, 20162, Italy
  • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
    Napoli, Campania, 80131, Italy
  • Local Institution - 304
    Napoli, Campania, 80131, Italy
  • I.R.C.C.S. Policlinico San Matteo
    Pavia, 27100, Italy
  • IRCCS Humanitas Clinical Institute
    Rozzano (milano), 20089, Italy
  • Local Institution - 602
    Chuo-ku, Tokyo 104-0045, Japan
  • National Cancer Center Hospital
    Chuo-ku, 104-0045, Japan
  • Tokai University Hospital
    Isehara City, Kanagawa, 259-1193, Japan
  • Aichi Cancer Center
    Nagoya, 464-8681, Japan
  • VU Academic Medical Center, Amsterdam
    Amsterdam, 1081 HV, Netherlands
  • UMC Groningen
    Groningen, 9713 GZ, Netherlands
  • Leids Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Erasmus Medical Center
    Rotterdam, 3015 CN, Netherlands
  • Local Institution - 501
    Rotterdam, 3015 CN, Netherlands
  • Local Institution - 402
    Plymouth, Devon PL6 8DH, United Kingdom
  • Local Institution - 407
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • St James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • UCL Cancer Institute
    London, WC1E 6BT, United Kingdom
  • Christie Hospital NHS Trust
    Manchester, M20 4BX, United Kingdom
  • Local Institution - 404
    Manchester, M20 4BX, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, Ng5 1PB, United Kingdom
  • Local Institution - 406
    Oxford, 0X3 7LE, United Kingdom
  • Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine
    Oxford, 0X3 7LE, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • Southampton University Hospitals NHS Trust
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Mar 2019, 33 months.

Results were first posted in Mar 2020, 1 year after primary completion.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's 33 months is below that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2016
First posted
Apr 11, 2016
StartActual
May 11, 2016
Primary completionActual
Mar 6, 2019
CompletionActual
Aug 21, 2022
Results first posted
Mar 18, 2020
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02733042
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 11, 2016
Start date
May 11, 2016
Primary completion
Mar 6, 2019
Completion
Aug 21, 2022
Results posted
Mar 18, 2020
Last update
Nov 18, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion